Clinical efficacy of treatment for subclinical-stage axial diabetic optic neuropathy
Journal Title: Офтальмологический журнал - Year 2018, Vol 0, Issue 4
Abstract
Background: There is no standard of therapy for the treatment of diabetic optic neuropathy (DON). Purpose: To assess the clinical efficacy of thioctic acid, topical brimonidine tartrate and a combination of vitamins В1, В6, and В12 in the management of subclinical-stage axial DON. Materials and Methods: Forty patients (63 eyes) were followed up after being diagnosed with subclinical-stage axial DON. The adjunct group was composed of 20 patients (32 eyes) who were administered (1) thioctic acid (Berlithion) at a dose of one 300 mg tablet a day for 42 days, (2) a 2 ml intramuscular injection of Milgamma, once per 3 days for 21 days, followed by switching to oral regimen, 1 tablet per 3 days for 21 days in two courses during a year, and (3) topical brimonidine tartrate 0.2%, 1-2 drops twice a day on a constant basis, as adjunctive to hypoglycemic therapy. The control group (20 patients; 31 eyes) received hypoglycemic therapy only. In addition to routine eye examination, retinal and optic nerve optical coherence tomography and electrophysiology were performed. Patients underwent an examination at baseline, 1.5 months, 6 months, 7.5 months, 13.5 months, 24 months and 25.5 months after treatment. Results: No progression of optic nerve damage was found in all 32 affected eyes of the adjunct group versus no progression, progression to mild-stage axial DON, and progression to advanced-stage axial DON in 64.5% (20 eyes), 35.5% (11 eyes) and 6.5% (2 eyes), respectively, of the controls at the 25.5-month time point. We found that our treatment attenuated the progression of optic nerve damage in subclinical-stage axial DON, with 25.9% better visual acuity, 29.5 % lower electrically evoked phosphene thresholds, 69.3% less ganglion cell complex (GCC) focal loss volume (FLV), and 29.8% less thickness of the cribriform plate compared to controls at 25.5 months. Conclusion: Our treatment was found to be clinically efficacious in attenuating the progression of optic nerve damage in subclinical-stage axial DON.
Authors and Affiliations
M. Karliychuk, P. Bezditko
Keywords
Related Articles
- EP ID EP423684
- DOI 10.31288/oftalmolzh201843236
- Views 83
- Downloads 0
Polymorphism of TGF-β1 (rs1800469) in children with different degrees of myopia
Background: TGF-β is a key intrascleral mediator of extracellular matrix remodeling. Purpose: To investigate the pattern of allele frequency and genotype distribution for TGF-β1 gene rs1800469 among the Ukrainian Podill...
Assessing OCTA changes in morphology and structure of retinal microvascular bed in patients with exudative AMD
Background: Optical coherence tomography angiography (OCTA) enables measuring characteristics of the retinal microvascular bed such as vascular plexus density and foveal avascular zone (FAZ) area. Purpose: To assess the...
Primary open-angle glaucoma progression depending on clinical indices at presentation
Background: Given the importance of developing simple and efficient methods for the diagnosis and prognosis of primary open-angle glaucoma (POAG), we have previously proposed an index of progression of glaucoma stage (IP...
Modelling form deprivation myopia in experiment
Background. Myopia, leading to visual function impairment, is one of the most topical issues in eye pathology. Although myopia is a common disease, its pathogenesis has a set of questions unstudied, which is why it is cr...
Comparison of morphometric changes in the chorioretinal complex after anti-VEGF treatment in patients with pathologic myopia versus those with neovascular age-related macular degeneration
Purpose: To compare morphometric changes in the chorioretinal complex after anti-vascular endothelial growth factor (anti-VEGF) treatment in patients with pathologic myopia (PM)-related choroidal neovascularization (CNV)...